72 HAMMERSMITH ROAD, LONDON, X0
Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Shareholder votes
Annual Report to Security Holders
Reports First Quarter 2025 Financial Results and Recent Business Highlights
Welcomes Tim McInerney to Board of Directors
Financial Results, Reg. FD
Q2
Q1
Amended Annual Report
FY 2023
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership